💥 Gate Square Event: #PTB Creative Contest# 💥
Post original content related to PTB, CandyDrop #77, or Launchpool on Gate Square for a chance to share 5,000 PTB rewards!
CandyDrop x PTB 👉 https://www.gate.com/zh/announcements/article/46922
PTB Launchpool is live 👉 https://www.gate.com/zh/announcements/article/46934
📅 Event Period: Sep 10, 2025 04:00 UTC – Sep 14, 2025 16:00 UTC
📌 How to Participate:
Post original content related to PTB, CandyDrop, or Launchpool
Minimum 80 words
Add hashtag: #PTB Creative Contest#
Include CandyDrop or Launchpool participation screenshot
🏆 Rewards:
🥇 1st
HSBC raises Sino Biopharmaceutical's target price to 58 Hong Kong dollars, with first-half revenue beating expectations
The September 16th data from Golden Ten shows that HSBC Global Research has released a report stating that Innovent Biologics (01801.HK) has exceeded the bank's and market expectations in the first half of the year, with promising prospects for PD-1 and IL-2, which can support business development opportunities. The buy rating is maintained, and the target price has been raised from 55 Hong Kong dollars to 58 Hong Kong dollars. The bank has raised its revenue forecast for 2024 to 2026 by 2 to 6%. HSBC Research expects Innovent Biologics' revenue from 2024 to 2026 to rise by 28 to 32%, reaching breakeven in 2025. Calculated at 8 times the 2024 price-to-sales ratio, breakeven is approaching, and with the launch of multiple innovative drugs from 2024 to 2025 as a catalyst, the valuation of Innovent Biologics is considered attractive.